Rallybio (RLYB) Tax Provisions (2020 - 2026)
Rallybio (RLYB) posted Tax Provisions of $1000.0 for Q4 2020.
Rallybio (RLYB) Tax Provisions (2020 - 2026) Analysis & Trends
Rallybio has reported Tax Provisions for 1 years, with the latest figure at $1000.0 in Q4 2020.
- Quarterly Tax Provisions changed N/A year-over-year to $1000.0 in Q4 2020, while the trailing twelve-month figure through Dec 2021 was $1000.0 (changed N/A YoY) and the FY2020 annual result came in at -$15000.0, changed N/A from the prior year.
- Tax Provisions held at $1000.0 in Q4 2020 per RLYB's latest filing.
- Over five years, Tax Provisions peaked at $1000.0 in Q4 2020 and troughed at $1000.0 in Q4 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 292.00 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 230.90 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 59.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 15.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 75.45 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 13.31 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -90.33 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.90 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Rallybio | 94.61 Mn | 94.61 Mn | - | 1.32 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.32 Mn |
| Dec 31, 2020 | 1,000.00 |